Quantitative assessment of multi-phase contrast-enhanced CT features in hepatic epithelioid hemangioendothelioma

肝上皮样血管内皮瘤多期增强CT特征的定量评估

阅读:2

Abstract

BACKGROUND: Hepatic epithelioid hemangioendothelioma (HEH) is a rare vascular malignancy with imaging features often overlapping with hepatic metastatic tumors (HMTs), leading to frequent misdiagnosis. Current diagnostic reliance on qualitative imaging signs lacks specificity, while biopsy-the gold standard-is invasive and impractical for multifocal lesions. The study aimed to assess the diagnostic performance of multi-phase contrast-enhanced computed tomography (CECT) in differentiating HEH from HMT. METHODS: This retrospective comparative study included 33 patients (mean age: 42.06 years; male: 27.27%) with histologically confirmed HEH and 36 patients (mean age: 64.22 years; male: 66.67%) with HMT between January 2017 and July 2024. Only non-coalescent hepatic lesions at the time of the initial emergence were analyzed to avoid confounding imaging features. Quantitative parameters including contrast enhancement ratio (CER), lesion-to-liver contrast ratio (LLC), arterial phase related absolute and relative percentage washout (APW(arterial) and RPW(arterial)), portal phase related absolute and relative percentage washout (APW(portal) and RPW(portal)) derived from multiphase hepatic CECT were evaluated and compared between HEH and HMT. Receiver operating characteristic (ROC) curve analysis was performed to determine the diagnostic performance of these parameters. RESULTS: The study found that APW(arterial), APW(portal) and RPW(portal) were significantly lower in HEH compared to HMT (P=0.01, P=0.001 and P=0.001, respectively). According to the ROC curve, APW(portal) and RPW(portal) showed moderate diagnostic significance with the area under the curve (AUC) values of 0.729 and 0.728, respectively. The cut-off values for APW(portal) and RPW(portal) were -17.08% and -6.90%, respectively. CONCLUSIONS: Multiphase CECT-derived parameters, particularly APW(portal) and RPW(portal), demonstrate potential value in differentiating HEH from HMT.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。